New biologic drug solrikitug aims to tame COPD inflammation
Disease control
Recruiting now
This Phase 2 trial tests solrikitug, a biologic drug given as a shot, in 171 adults with moderate-to-severe COPD and high eosinophil levels. The study compares two doses of solrikitug against a placebo to see if it safely reduces inflammation and improves lung function over time.…
Phase: PHASE2 • Sponsor: Uniquity One (UNI) • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC